HomeBUSINESS
BUSINESS

YL Biologics’ Enbrel Biosimilar Shows Equivalent Efficacy to Originator
(Feb.8.2018)

A biosimilar version of the rheumatoid arthritis (RA) med Enbrel (etanercept) being developed by YL Biologics, a joint venture between Toyama-based Yoshindo and Indian generic maker Lupin, showed equivalent efficacy to the originator product, the three companies said on February 7 ...
(LOG IN FOR FULL STORY)

News Calendar